Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Mini-Tabs Plus Ribavirin for Children Aged 3–11 Years with Hepatitis C Genotype 1a

INTRODUCTION: To assess the safety, efficacy, and pharmacokinetics of mini-tablet formulations of ombitasvir (OBV), paritaprevir (PTV), ritonavir, and dasabuvir (DSV) with or without ribavirin for 12 weeks in children infected with chronic hepatitis C virus (HCV) genotype (GT) 1. METHODS: This is an...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosenthal, Philip, Narkewicz, Michael R., Yao, Betty B., Jolley, Christopher D., Lobritto, Steven J., Wen, Jessica, Molleston, Jean P., Hsu, Evelyn K., Jonas, Maureen M., Zha, Jiuhong, Liu, Li, Leung, Daniel H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7467405/
https://www.ncbi.nlm.nih.gov/pubmed/32451952
http://dx.doi.org/10.1007/s12325-020-01389-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7467405/
https://www.ncbi.nlm.nih.gov/pubmed/32451952
http://dx.doi.org/10.1007/s12325-020-01389-9

Ejemplares similares